Wednesday, May 10, 2023
Mitsubishi Tanabe Pharma Corporation announced that its wholly owned subsidiary, Mitsubishi Tanabe Pharma obtained the approval from Authority of Switzerland (Swissmedic) to RADICAVA® Oral Suspension for the indication of amyotrophic lateral sclerosis. RADICAVA® Oral Suspension will be commercialised by MTPD in Switzerland.
RADICAVA® Oral Suspension offers the same efficacy as edaravone for intravenous infusion, a treatment shown in a pivotal trial to help slow the loss of physical function in ALS. RADICAVA® Oral Suspension formulation serves as a new treatment option for ALS patients in order to address unmet needs of people living with ALS.
RADICAVA® Oral Suspension is specifically formulated for patients with ALS and provides a flexible administration option with a 5ml dose taken orally or via feeding tube. One cycle of administration of RADICAVA® Oral Suspension is a total of 28 days, including both the dosing period and the drug-free period, and that cycle is repeated.
RADICAVA® Oral Suspension are available in bottles and do not require water or solution to administer. RADICAVA® Oral Suspension needs to be refrigerated during the distribution process and in pharmacies, but patients can keep it at room temperature.
